Digital health companies Glooko and Hedia have launched their personalised bolus insulin dosing management solution for people with Type 1 and Type 2 diabetes in the UK.
The new interoperable solution combines connected care, remote patient monitoring, and digital therapeutic technologies from the two companies.
Currently launched in the UK, the solution will be extended to other European countries.
In April 2023, Glooko and Hedia entered a global collaboration to integrate Hedia’s insulin dosing algorithm into Glooko’s diabetes management platforms.
Hedia CEO Lars Christian Lund said: “We are thrilled to be partnering with Glooko, a digital health company with an extensive clinical network.
“This joint offering is perfectly aligned with Hedia’s vision to improve the quality of life for people with diabetes and make the best diabetes management tools available.
“In addition to our strong clinical evidence, one of the key issues we consider when building our technology is regulatory compliance, and we recently got MDR certified in Europe.
“Hedia’s Class IIb medical device designation ensures that patients and their care teams are getting the best solutions.”
Bolus is an extra dose of insulin taken to address the increase in blood sugar due to an expected meal or snack.
Calculating the correct dose can be challenging for patients who do not use an insulin pump.
Glooko’s platform allows patients to share their blood glucose readings, insulin doses, food and carbs, exercise activity, blood pressure, and weight, with healthcare providers (HCPs).
Hedia’s Diabetes Assistant, integrated with Glooko’s platform, provides patients with personalised support in calculating insulin doses and simplifies diabetes management.
The integrated solution provides HCPs with enhanced access to their patients’ health data, including blood glucose readings, insulin doses, carbohydrate intake, physical activity, and more.
The simplified approach to managing multiple daily injections improves both patient outcomes and provider efficiency in remote and in-person care settings, said Glooko.
Glooko CEO Mike Alvarez said: “We are very pleased to bring this algorithm-driven, personalised innovation to diabetes patients and their healthcare teams through our partnership with Hedia.
“With extensive clinical data supporting Hedia’s efficacy, this solution provides an alternative for those unable to access insulin pumps, ensuring more effective management of MDI therapy.
“This partnership reflects Glooko’s commitment to advancing digital health tools that optimise diabetes care and help stabilise blood glucose levels through personalised, connected care.”
